Jasmin Hundal, Chair of Hematology-Oncology Research Fellowship Working Group at Cleveland Clinic, shared a post on LinkedIn:
“Excited to share our latest publication examining cardiometabolic health in patients with early-stage triple-negative breast cancer treated with the KEYNOTE-522 regimen.
A key finding: while metabolic syndrome did not impact pathologic complete response rates, BUT metabolic syndrome, hypertension and diabetes were independently associated with worse overall survival.
These findings add to a growing body of literature suggesting that cardiometabolic health may influence cancer outcomes beyond traditional tumor-related factors.
We have been focusing on tumor biology, but we are increasingly recognizing that host biology matters too. The growing field of metabo-oncology is revealing how metabolic health may influence cancer outcomes, treatment tolerance, and survivorship.
As interest grows in lifestyle interventions, GLP-1 therapies, and other metabolic approaches, optimizing cardiometabolic health may become an important component of comprehensive cancer care and not just cancer prevention.
Grateful to my co-authors, mentors, and collaborators for making this work possible.”
Title: Impact of cardiometabolic health on treatment outcomes in early-stage triple-negative breast cancer receiving chemoimmunotherapy
Authors: Jasmin Hundal, Asfand Cheema, Akram Abushamma, Kirti Arora, Xiaoying Chen, Kelly Fargo, Maiti Baidehi
Read the Full Article.
